JP2005519958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519958A5 JP2005519958A5 JP2003575901A JP2003575901A JP2005519958A5 JP 2005519958 A5 JP2005519958 A5 JP 2005519958A5 JP 2003575901 A JP2003575901 A JP 2003575901A JP 2003575901 A JP2003575901 A JP 2003575901A JP 2005519958 A5 JP2005519958 A5 JP 2005519958A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- methyl
- methylpropanamide
- methylpropyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 455
- -1 and cycloheteroalkyl Chemical group 0.000 claims description 207
- 125000000217 alkyl group Chemical group 0.000 claims description 106
- 150000001875 compounds Chemical class 0.000 claims description 77
- 125000001072 heteroaryl group Chemical group 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 64
- 125000001424 substituent group Chemical group 0.000 claims description 62
- VSNDXBUJNXNURF-UHFFFAOYSA-N 2-(3,5-dichlorophenoxy)-2-methylhexanamide Chemical compound CCCCC(C)(C(N)=O)OC1=CC(Cl)=CC(Cl)=C1 VSNDXBUJNXNURF-UHFFFAOYSA-N 0.000 claims description 52
- 150000001408 amides Chemical class 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- ASFIPARRHCLIOR-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 ASFIPARRHCLIOR-UHFFFAOYSA-N 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 15
- 235000014632 disordered eating Nutrition 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- WADFFGDAIJGNFH-UHFFFAOYSA-N 2-(3-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(Cl)=C1 WADFFGDAIJGNFH-UHFFFAOYSA-N 0.000 claims description 14
- JQWPFJSGBASENO-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-pyridin-3-ylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=NC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JQWPFJSGBASENO-UHFFFAOYSA-N 0.000 claims description 14
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 14
- DDETYHPHEUZUCX-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-(3,5-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(F)=C1 DDETYHPHEUZUCX-UHFFFAOYSA-N 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- MRECCTXLXCELBU-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3,5-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(F)=C1 MRECCTXLXCELBU-UHFFFAOYSA-N 0.000 claims description 13
- KSKXQOGPSBZBSW-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-pyridin-2-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=N1 KSKXQOGPSBZBSW-UHFFFAOYSA-N 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- KJLZSBFYCZPSJB-UHFFFAOYSA-N 2-(3-chloro-5-fluorophenoxy)-n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(Cl)=C1 KJLZSBFYCZPSJB-UHFFFAOYSA-N 0.000 claims description 12
- UFQVTGSROPGOQC-UHFFFAOYSA-N 2-(3-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=CC(Cl)=C1 UFQVTGSROPGOQC-UHFFFAOYSA-N 0.000 claims description 12
- RGCCRDDNINAOKY-UHFFFAOYSA-N 2-(3-chlorophenoxy)-n-[4-(4-cyanophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(C#N)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(Cl)=C1 RGCCRDDNINAOKY-UHFFFAOYSA-N 0.000 claims description 12
- VTTREAPVLCATHS-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-pyridin-2-ylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1N=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 VTTREAPVLCATHS-UHFFFAOYSA-N 0.000 claims description 12
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 12
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 12
- 208000030814 Eating disease Diseases 0.000 claims description 12
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000037406 food intake Effects 0.000 claims description 12
- 235000012631 food intake Nutrition 0.000 claims description 12
- JRBXUPSPFIMRED-UHFFFAOYSA-N methyl 4-[3-[[2-(4-fluorophenoxy)-2-methylpropanoyl]amino]-2-phenylbutyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 JRBXUPSPFIMRED-UHFFFAOYSA-N 0.000 claims description 12
- HAMLZAXSMZZNHH-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(4-chlorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 HAMLZAXSMZZNHH-UHFFFAOYSA-N 0.000 claims description 12
- HFHWAGKVYAUKHZ-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 HFHWAGKVYAUKHZ-UHFFFAOYSA-N 0.000 claims description 12
- SCGDHVOMGFBTMI-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-methyl-2-pyridin-2-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=N1 SCGDHVOMGFBTMI-UHFFFAOYSA-N 0.000 claims description 12
- UYTUXABSUBMTPQ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(5-chloropyridin-3-yl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(Cl)C=NC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 UYTUXABSUBMTPQ-UHFFFAOYSA-N 0.000 claims description 12
- OXJWNDULCQMQGA-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-pyridin-3-ylbutan-2-yl]-2-(3,5-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=NC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(F)=C1 OXJWNDULCQMQGA-UHFFFAOYSA-N 0.000 claims description 12
- AFCBFUABPBPHLV-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-pyridin-3-ylbutan-2-yl]-2-(3-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=NC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(F)=C1 AFCBFUABPBPHLV-UHFFFAOYSA-N 0.000 claims description 12
- KYYIJERVQWQVHB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[2-(4-chlorophenoxy)-2-(4-chlorophenyl)ethyl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1OC(C=1C=CC(Cl)=CC=1)CNC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYYIJERVQWQVHB-UHFFFAOYSA-N 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- GPGIORBDLOZMBV-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methyl-2-(6-methylpyridin-3-yl)oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C)N=C1 GPGIORBDLOZMBV-UHFFFAOYSA-N 0.000 claims description 11
- OJIWFBIZHVEQBL-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3,4-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C(F)=C1 OJIWFBIZHVEQBL-UHFFFAOYSA-N 0.000 claims description 11
- PAHGBCUEXOTPIT-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(F)=C1 PAHGBCUEXOTPIT-UHFFFAOYSA-N 0.000 claims description 11
- UVFJWLJLMVGLGK-UHFFFAOYSA-N 2-(3,5-difluorophenoxy)-2-methylhexanamide Chemical compound C(CC)CC(C(=O)N)(C)OC1=CC(=CC(=C1)F)F UVFJWLJLMVGLGK-UHFFFAOYSA-N 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- PJNUOTNCBCRWHQ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3,5-difluorophenyl)butan-2-yl]-2-(3,5-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=C(F)C=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(F)=C1 PJNUOTNCBCRWHQ-UHFFFAOYSA-N 0.000 claims description 10
- QLYKJCMUNUWAGO-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QLYKJCMUNUWAGO-UHFFFAOYSA-N 0.000 claims description 10
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 10
- VBIHTHXHJPLTBR-UHFFFAOYSA-N 2-(3-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(Cl)=C1 VBIHTHXHJPLTBR-UHFFFAOYSA-N 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- CFCFDFUEJMXRLW-UHFFFAOYSA-N 2-(3-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-pyridin-3-ylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=NC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(Cl)=C1 CFCFDFUEJMXRLW-UHFFFAOYSA-N 0.000 claims description 8
- PICQEYPJHIMZHP-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[3-(2-chlorophenyl)-4-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(C=1C(=CC=CC=1)Cl)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 PICQEYPJHIMZHP-UHFFFAOYSA-N 0.000 claims description 8
- BBGPOWKMPKCETL-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[3-(4-chlorophenyl)-4-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BBGPOWKMPKCETL-UHFFFAOYSA-N 0.000 claims description 8
- FITSQWWWCJRSMA-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-(3,5-difluorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=C(F)C=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 FITSQWWWCJRSMA-UHFFFAOYSA-N 0.000 claims description 8
- FGJHUABKMGQONH-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 FGJHUABKMGQONH-UHFFFAOYSA-N 0.000 claims description 8
- SZTZUGGWPZIINA-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 SZTZUGGWPZIINA-UHFFFAOYSA-N 0.000 claims description 8
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 8
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 claims description 8
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 8
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims description 8
- ZBFSKHCQHWULCZ-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methyl-2-phenoxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=C1 ZBFSKHCQHWULCZ-UHFFFAOYSA-N 0.000 claims description 8
- NJSONKDWRVNYCL-UHFFFAOYSA-N n-[3-(3-cyanophenyl)-4-cyclobutylbutan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C1CCC1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 NJSONKDWRVNYCL-UHFFFAOYSA-N 0.000 claims description 8
- TZYRPDAFSAFZSQ-UHFFFAOYSA-N n-[3-(3-cyanophenyl)-4-cyclopentylbutan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C1CCCC1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 TZYRPDAFSAFZSQ-UHFFFAOYSA-N 0.000 claims description 8
- OFJSMCUUQUZKND-UHFFFAOYSA-N n-[3-(4-chloro-2-fluorophenyl)-3-(4-chlorophenyl)butan-2-yl]-2-(4-chlorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C)(C=1C(=CC(Cl)=CC=1)F)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 OFJSMCUUQUZKND-UHFFFAOYSA-N 0.000 claims description 8
- BINCMSJEDLRTJN-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-methylphenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(C)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 BINCMSJEDLRTJN-UHFFFAOYSA-N 0.000 claims description 8
- IROBMYGWVLTDFP-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-phenoxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=C1 IROBMYGWVLTDFP-UHFFFAOYSA-N 0.000 claims description 8
- JTCSTBJLAUGXMC-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-pyridin-3-ylbutan-2-yl]-2-(3,5-dichlorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=NC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(Cl)=CC(Cl)=C1 JTCSTBJLAUGXMC-UHFFFAOYSA-N 0.000 claims description 8
- WDRZQEUNPQWHSG-UHFFFAOYSA-N n-[3-(3-cyanophenyl)-4-cyclohexylbutan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C1CCCCC1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 WDRZQEUNPQWHSG-UHFFFAOYSA-N 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- QXLRCSNJDDZHMP-UHFFFAOYSA-N 2-(2-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=C1Cl QXLRCSNJDDZHMP-UHFFFAOYSA-N 0.000 claims description 6
- HIFGCYYBGHLQMV-HTAPYJJXSA-N 2-(3-chloro-4-fluorophenoxy)-n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=C(F)C(Cl)=C1 HIFGCYYBGHLQMV-HTAPYJJXSA-N 0.000 claims description 6
- YDJYVTJJCOWWAN-UHFFFAOYSA-N 2-(3-chloro-5-fluorophenoxy)-n-[4-(4-chlorophenyl)-3-pyridin-3-ylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=NC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(Cl)=C1 YDJYVTJJCOWWAN-UHFFFAOYSA-N 0.000 claims description 6
- DHMCZTXHSCFLCI-HTAPYJJXSA-N 2-(4-chloro-3-fluorophenoxy)-n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=C(Cl)C(F)=C1 DHMCZTXHSCFLCI-HTAPYJJXSA-N 0.000 claims description 6
- VGAKJPBJPLSUNB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-2-methyl-n-(5-methyl-3-phenylhexan-2-yl)propanamide Chemical compound C=1C=CC=CC=1C(CC(C)C)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 VGAKJPBJPLSUNB-UHFFFAOYSA-N 0.000 claims description 6
- HLQRTQRYEWMHSE-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[3-(4-chlorophenyl)-3-(4-chlorophenyl)sulfanylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1SC(C)(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 HLQRTQRYEWMHSE-UHFFFAOYSA-N 0.000 claims description 6
- SAAXYWSPRMMLPA-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[3-(4-chlorophenyl)-4-(2,4-dichlorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 SAAXYWSPRMMLPA-UHFFFAOYSA-N 0.000 claims description 6
- UAQZEOXBFRPEBY-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-(2-fluorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C(=CC=CC=1)F)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 UAQZEOXBFRPEBY-UHFFFAOYSA-N 0.000 claims description 6
- BDRJZRQBNUXBTR-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-pyridin-4-ylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CN=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BDRJZRQBNUXBTR-UHFFFAOYSA-N 0.000 claims description 6
- YDCTWGDCYUTKLP-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-fluorophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 YDCTWGDCYUTKLP-UHFFFAOYSA-N 0.000 claims description 6
- HIJCBCZZWCRRET-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-[3-(4-methoxyphenyl)-4-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C1=CC(OC)=CC=C1C(C(C)NC(=O)C(C)(C)OC=1C=CC(F)=CC=1)CC1=CC=CC=C1 HIJCBCZZWCRRET-UHFFFAOYSA-N 0.000 claims description 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 6
- IPKDNRMCLOIXMK-UHFFFAOYSA-N N-[1-(4-chlorophenyl)butan-2-yloxy]-2-(3,5-dichlorophenoxy)-2-methylhexanamide Chemical compound C(CC)CC(C(=O)NOC(CC)CC1=CC=C(C=C1)Cl)(C)OC1=CC(=CC(=C1)Cl)Cl IPKDNRMCLOIXMK-UHFFFAOYSA-N 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 6
- 125000005110 aryl thio group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- BESSNFSJYMKGMD-UHFFFAOYSA-N n-(3,4-diphenylbutan-2-yl)-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 BESSNFSJYMKGMD-UHFFFAOYSA-N 0.000 claims description 6
- DDRSCAPJGQMMOK-UHFFFAOYSA-N n-(3-benzyl-4-phenylbutan-2-yl)-2-(4-chlorophenoxy)-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(CC=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 DDRSCAPJGQMMOK-UHFFFAOYSA-N 0.000 claims description 6
- HMDZUJRWCVTDOM-HTAPYJJXSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3,4-dichlorophenoxy)-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=C(Cl)C(Cl)=C1 HMDZUJRWCVTDOM-HTAPYJJXSA-N 0.000 claims description 6
- XLZDVTNCFPUPNX-BXKMTCNYSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3,5-dichlorophenoxy)-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC(Cl)=CC(Cl)=C1 XLZDVTNCFPUPNX-BXKMTCNYSA-N 0.000 claims description 6
- JJSXACIYQNLZJM-HRAATJIYSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-(3,4,5-trifluorophenoxy)propanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC(F)=C(F)C(F)=C1 JJSXACIYQNLZJM-HRAATJIYSA-N 0.000 claims description 6
- KRWJZJVGUIDRLO-UHFFFAOYSA-N n-[2,2-bis(4-chlorophenyl)ethyl]-2-(4-chlorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C=1C=CC(Cl)=CC=1)CNC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KRWJZJVGUIDRLO-UHFFFAOYSA-N 0.000 claims description 6
- WHRZHYPAWOQKQK-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(2-chlorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=C1Cl WHRZHYPAWOQKQK-UHFFFAOYSA-N 0.000 claims description 6
- FNCWTFNCJCSDOW-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(2-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=C1F FNCWTFNCJCSDOW-UHFFFAOYSA-N 0.000 claims description 6
- GEOIUTVAVWSNLE-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(3,4-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C(F)=C1 GEOIUTVAVWSNLE-UHFFFAOYSA-N 0.000 claims description 6
- SEDJSZAOVHYSAF-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(3-chlorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(Cl)=C1 SEDJSZAOVHYSAF-UHFFFAOYSA-N 0.000 claims description 6
- KXJMVFULYOBYMN-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-cyclohexyloxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1CCCCC1 KXJMVFULYOBYMN-UHFFFAOYSA-N 0.000 claims description 6
- ZNSNZQPZEYYRPV-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methyl-2-pyridin-2-yloxybutanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(CC)OC1=CC=CC=N1 ZNSNZQPZEYYRPV-UHFFFAOYSA-N 0.000 claims description 6
- UXXTYBHPNIIBCB-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methyl-2-pyridin-3-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CN=C1 UXXTYBHPNIIBCB-UHFFFAOYSA-N 0.000 claims description 6
- BOZMULZMZSTLNE-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methyl-2-pyridin-4-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=NC=C1 BOZMULZMZSTLNE-UHFFFAOYSA-N 0.000 claims description 6
- RJTPJZRSEMUBKR-UHFFFAOYSA-N n-[3-(2-chlorophenyl)-4-phenylbutan-2-yl]-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(C=1C(=CC=CC=1)Cl)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 RJTPJZRSEMUBKR-UHFFFAOYSA-N 0.000 claims description 6
- SPSJRZBNCFXKKY-UHFFFAOYSA-N n-[3-(3-cyanophenyl)-5-methylhexan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=CC(C#N)=CC=1C(CC(C)C)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 SPSJRZBNCFXKKY-UHFFFAOYSA-N 0.000 claims description 6
- VQPQLXTYJFAUNV-UHFFFAOYSA-N n-[3-(4-chlorophenyl)-4-phenylbutan-2-yl]-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 VQPQLXTYJFAUNV-UHFFFAOYSA-N 0.000 claims description 6
- RAUJPFCUCFXTMG-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 RAUJPFCUCFXTMG-UHFFFAOYSA-N 0.000 claims description 6
- PGLMEBMLJVTKBN-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-(5-chloropyridin-2-yl)oxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=N1 PGLMEBMLJVTKBN-UHFFFAOYSA-N 0.000 claims description 6
- ILUAOSMOKCIAFT-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(2-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=C1F ILUAOSMOKCIAFT-UHFFFAOYSA-N 0.000 claims description 6
- JODYBLNZGKLUHE-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-cyclohexyloxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1CCCCC1 JODYBLNZGKLUHE-UHFFFAOYSA-N 0.000 claims description 6
- NREJKDPSMIXZLX-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-pyridin-2-yloxybutanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(CC)OC1=CC=CC=N1 NREJKDPSMIXZLX-UHFFFAOYSA-N 0.000 claims description 6
- MJDFMECYCIGIDO-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-pyridin-3-ylbutan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=NC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 MJDFMECYCIGIDO-UHFFFAOYSA-N 0.000 claims description 6
- DGBMQSXBPXBKAM-UHFFFAOYSA-N n-[4-(5-chloropyridin-2-yl)-3-phenylbutan-2-yl]-2-(3,5-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=NC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(F)=C1 DGBMQSXBPXBKAM-UHFFFAOYSA-N 0.000 claims description 6
- ZLRSQTMAGSCJBZ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-2-methyl-n-[3-phenyl-4-[4-(trifluoromethyl)phenyl]butan-2-yl]propanamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 ZLRSQTMAGSCJBZ-UHFFFAOYSA-N 0.000 claims description 5
- YLKDYXSLDXMMBF-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(1,2-diphenylpentan-3-yl)-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC=CC=1)C(CC)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 YLKDYXSLDXMMBF-UHFFFAOYSA-N 0.000 claims description 5
- UNIXCKUMWRLUBV-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(3,4-diphenylbutan-2-yl)-2-methylpropanamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 UNIXCKUMWRLUBV-UHFFFAOYSA-N 0.000 claims description 5
- FFALVHGQANUEKB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(2-chlorophenyl)-3-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C=1C=CC=C(Cl)C=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 FFALVHGQANUEKB-UHFFFAOYSA-N 0.000 claims description 5
- QGNXBJNFYAPCJQ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-(4-fluorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(F)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 QGNXBJNFYAPCJQ-UHFFFAOYSA-N 0.000 claims description 5
- DYVOFFWCKVALME-UHFFFAOYSA-N methyl 4-[3-[[2-(4-chlorophenoxy)-2-methylpropanoyl]amino]-2-phenylbutyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 DYVOFFWCKVALME-UHFFFAOYSA-N 0.000 claims description 5
- MRECCTXLXCELBU-BXKMTCNYSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3,5-difluorophenoxy)-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC(F)=CC(F)=C1 MRECCTXLXCELBU-BXKMTCNYSA-N 0.000 claims description 5
- RDLDSTNJWGCIMS-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(3,5-difluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(F)=CC(F)=C1 RDLDSTNJWGCIMS-UHFFFAOYSA-N 0.000 claims description 5
- ADGPIQXYKJHCTR-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(3-cyanophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(C#N)=C1 ADGPIQXYKJHCTR-UHFFFAOYSA-N 0.000 claims description 5
- RKOAMTYPZBEQQS-UHFFFAOYSA-N n-[3-(4-chloro-2-fluorophenyl)-3-(4-chlorophenyl)butan-2-yl]-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C)(C=1C(=CC(Cl)=CC=1)F)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 RKOAMTYPZBEQQS-UHFFFAOYSA-N 0.000 claims description 5
- WMAIMIWPXKZNQY-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-(6-methylpyridin-3-yl)oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C)N=C1 WMAIMIWPXKZNQY-UHFFFAOYSA-N 0.000 claims description 5
- IFMIHWYHYXZLKK-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-pyridin-4-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=NC=C1 IFMIHWYHYXZLKK-UHFFFAOYSA-N 0.000 claims description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
- QYQVDCKQMLVAIA-CXUHLZMHSA-N (e)-n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-phenylprop-2-enamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)\C=C\C1=CC=CC=C1 QYQVDCKQMLVAIA-CXUHLZMHSA-N 0.000 claims description 4
- YWAIFKOZVPTDAI-UHFFFAOYSA-N 1-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-(4-chlorophenyl)urea Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)NC1=CC=C(Cl)C=C1 YWAIFKOZVPTDAI-UHFFFAOYSA-N 0.000 claims description 4
- YWRGIVVYYWLYII-UHFFFAOYSA-N 1-[3-(5-bromopyridin-3-yl)-4-(4-chlorophenyl)butan-2-yl]-4-[(2-methylpropan-2-yl)oxy]-6-(trifluoromethyl)-2H-pyrimidine Chemical compound BrC=1C=C(C=NC1)C(C(C)N1CN=C(C=C1C(F)(F)F)OC(C)(C)C)CC1=CC=C(C=C1)Cl YWRGIVVYYWLYII-UHFFFAOYSA-N 0.000 claims description 4
- OZDZYASFKLTUMW-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-3-(5-chloropyridin-3-yl)butan-2-yl]-2-[(2-methylpropan-2-yl)oxy]-4-(trifluoromethyl)-2H-pyrimidine Chemical compound ClC1=CC=C(C=C1)CC(C(C)N1C(N=C(C=C1)C(F)(F)F)OC(C)(C)C)C=1C=NC=C(C=1)Cl OZDZYASFKLTUMW-UHFFFAOYSA-N 0.000 claims description 4
- WEIISNFSPRUXIK-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-3-(5-chloropyridin-3-yl)butan-2-yl]-4-[(2-methylpropan-2-yl)oxy]-6-(trifluoromethyl)-2H-pyrimidine Chemical compound ClC1=CC=C(C=C1)CC(C(C)N1CN=C(C=C1C(F)(F)F)OC(C)(C)C)C=1C=NC=C(C1)Cl WEIISNFSPRUXIK-UHFFFAOYSA-N 0.000 claims description 4
- GBYVFTDQEYFWAK-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-3-(5-fluoropyridin-3-yl)butan-2-yl]-4-[(2-methylpropan-2-yl)oxy]-6-(trifluoromethyl)-2H-pyrimidine Chemical compound ClC1=CC=C(C=C1)CC(C(C)N1CN=C(C=C1C(F)(F)F)OC(C)(C)C)C=1C=NC=C(C1)F GBYVFTDQEYFWAK-UHFFFAOYSA-N 0.000 claims description 4
- UGNVHARNSBSSNW-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-3-[3-(trifluoromethyl)phenyl]butan-2-yl]-2-[(2-methylpropan-2-yl)oxy]-5-(trifluoromethyl)-2H-pyridine Chemical compound ClC1=CC=C(C=C1)CC(C(C)N1C(C=CC(=C1)C(F)(F)F)OC(C)(C)C)C1=CC(=CC=C1)C(F)(F)F UGNVHARNSBSSNW-UHFFFAOYSA-N 0.000 claims description 4
- RBBYBIBMLSARDO-UHFFFAOYSA-N 2-(4-chloroanilino)-n-(3,4-diphenylbutan-2-yl)acetamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)CNC1=CC=C(Cl)C=C1 RBBYBIBMLSARDO-UHFFFAOYSA-N 0.000 claims description 4
- PJNPDYNTGUXXRS-UHFFFAOYSA-N 2-(4-chloroanilino)-n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)CNC1=CC=C(Cl)C=C1 PJNPDYNTGUXXRS-UHFFFAOYSA-N 0.000 claims description 4
- CGQAPRJYOLLYRZ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(3,4-diphenylbutan-2-yl)acetamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)COC1=CC=C(Cl)C=C1 CGQAPRJYOLLYRZ-UHFFFAOYSA-N 0.000 claims description 4
- IBPWXVZEVAQZEN-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(3,4-diphenylbutan-2-yl)propanamide Chemical compound C=1C=CC=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)OC1=CC=C(Cl)C=C1 IBPWXVZEVAQZEN-UHFFFAOYSA-N 0.000 claims description 4
- NBWKZNSAUDAIJT-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(3,6-diphenylhexan-2-yl)acetamide Chemical compound C=1C=CC=CC=1CCCC(C=1C=CC=CC=1)C(C)NC(=O)COC1=CC=C(Cl)C=C1 NBWKZNSAUDAIJT-UHFFFAOYSA-N 0.000 claims description 4
- QVLXRMGWTQDRDE-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(3-phenylhexan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(CCC)C(C)NC(=O)COC1=CC=C(Cl)C=C1 QVLXRMGWTQDRDE-UHFFFAOYSA-N 0.000 claims description 4
- GOMJOOLWPQTOJH-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(4-methyl-3-phenylpentan-2-yl)propanamide Chemical compound C=1C=CC=CC=1C(C(C)C)C(C)NC(=O)C(C)OC1=CC=C(Cl)C=C1 GOMJOOLWPQTOJH-UHFFFAOYSA-N 0.000 claims description 4
- KVTYQUDPRXFHPX-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-(2,4-dichlorophenyl)butan-2-yl]-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C(=CC(Cl)=CC=1)Cl)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KVTYQUDPRXFHPX-UHFFFAOYSA-N 0.000 claims description 4
- ITWKWMDRYHXZNY-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)COC1=CC=C(Cl)C=C1 ITWKWMDRYHXZNY-UHFFFAOYSA-N 0.000 claims description 4
- GOOBLKKFKDKVCH-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]propanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)OC1=CC=C(Cl)C=C1 GOOBLKKFKDKVCH-UHFFFAOYSA-N 0.000 claims description 4
- CTYYYUONAUKEFU-UHFFFAOYSA-N 3,4-bis(4-chlorophenyl)butan-2-yl-tert-butylcarbamic acid Chemical compound C=1C=C(Cl)C=CC=1C(C(C)N(C(O)=O)C(C)(C)C)CC1=CC=C(Cl)C=C1 CTYYYUONAUKEFU-UHFFFAOYSA-N 0.000 claims description 4
- RYYYVEMIHJLCQP-UHFFFAOYSA-N 5-[1-(4-chlorophenyl)-3-[4-[(2-methylpropan-2-yl)oxy]-6-(trifluoromethyl)-2H-pyrimidin-1-yl]butan-2-yl]pyridine-3-carbonitrile Chemical compound ClC1=CC=C(C=C1)CC(C(C)N1CN=C(C=C1C(F)(F)F)OC(C)(C)C)C=1C=NC=C(C1)C#N RYYYVEMIHJLCQP-UHFFFAOYSA-N 0.000 claims description 4
- WMVMNFLXZIKMFR-UHFFFAOYSA-N 5-oxo-2-phenylpentanamide Chemical compound NC(=O)C(CCC=O)c1ccccc1 WMVMNFLXZIKMFR-UHFFFAOYSA-N 0.000 claims description 4
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical group NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- HOTUDSNEFUMXHW-UHFFFAOYSA-N N-[4-(4-chlorophenyl)hexan-3-yloxy]-2-(3,5-dichlorophenoxy)-2-methylhexanamide Chemical compound C(CC)CC(C(=O)NOC(CC)C(CC)C1=CC=C(C=C1)Cl)(C)OC1=CC(=CC(=C1)Cl)Cl HOTUDSNEFUMXHW-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- VGXVGVLUSMHCIK-OXJNMPFZSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-[4-(trifluoromethyl)pyrimidin-2-yl]oxypropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=NC=CC(C(F)(F)F)=N1 VGXVGVLUSMHCIK-OXJNMPFZSA-N 0.000 claims description 4
- SHYMGIFYVAQSQP-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2,2-dimethyl-3-phenylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)CC1=CC=CC=C1 SHYMGIFYVAQSQP-UHFFFAOYSA-N 0.000 claims description 4
- RVAWHCFCSWUJKL-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(3-chlorophenyl)acetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)CC1=CC=CC(Cl)=C1 RVAWHCFCSWUJKL-UHFFFAOYSA-N 0.000 claims description 4
- VJTHLBLSXRKYBS-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(3-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(F)=C1 VJTHLBLSXRKYBS-UHFFFAOYSA-N 0.000 claims description 4
- WVFKSOOBEAEOLB-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(4-chloroanilino)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)NC1=CC=C(Cl)C=C1 WVFKSOOBEAEOLB-UHFFFAOYSA-N 0.000 claims description 4
- OOAVFDITBMDQHO-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-(6-methoxy-3-oxo-1,2-dihydroinden-1-yl)acetamide Chemical compound C12=CC(OC)=CC=C2C(=O)CC1CC(=O)NC(C)C(C=1C=CC(Cl)=CC=1)CC1=CC=C(Cl)C=C1 OOAVFDITBMDQHO-UHFFFAOYSA-N 0.000 claims description 4
- ZQPOJTGUJGYLKV-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-cyclopentylacetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)CC1CCCC1 ZQPOJTGUJGYLKV-UHFFFAOYSA-N 0.000 claims description 4
- ZTULVYZILKSREY-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-cyclopropylacetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)CC1CC1 ZTULVYZILKSREY-UHFFFAOYSA-N 0.000 claims description 4
- NXRBLLZHCOUNLB-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-ethoxyacetamide Chemical compound C=1C=C(Cl)C=CC=1C(C(C)NC(=O)COCC)CC1=CC=C(Cl)C=C1 NXRBLLZHCOUNLB-UHFFFAOYSA-N 0.000 claims description 4
- FKZVNMVQHUPANG-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-hydroxy-2,2-diphenylacetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 FKZVNMVQHUPANG-UHFFFAOYSA-N 0.000 claims description 4
- YSTFROUXDKFTKZ-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-hydroxy-2-phenylacetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(O)C1=CC=CC=C1 YSTFROUXDKFTKZ-UHFFFAOYSA-N 0.000 claims description 4
- JTRLTPDZMMSABJ-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methoxy-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(OC)C(=O)NC(C)C(C=1C=CC(Cl)=CC=1)CC1=CC=C(Cl)C=C1 JTRLTPDZMMSABJ-UHFFFAOYSA-N 0.000 claims description 4
- MJPKFOUKFPDHTB-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methyl-2-pyridin-2-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=N1 MJPKFOUKFPDHTB-UHFFFAOYSA-N 0.000 claims description 4
- KGNWNVCZBUWYRA-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-methyl-3-phenylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)CC1=CC=CC=C1 KGNWNVCZBUWYRA-UHFFFAOYSA-N 0.000 claims description 4
- LIPBZQQZVUTATK-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-naphthalen-1-ylacetamide Chemical compound C=1C=CC2=CC=CC=C2C=1CC(=O)NC(C)C(C=1C=CC(Cl)=CC=1)CC1=CC=C(Cl)C=C1 LIPBZQQZVUTATK-UHFFFAOYSA-N 0.000 claims description 4
- FKRNGWAIPKZKJV-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-phenoxyacetamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)COC1=CC=CC=C1 FKRNGWAIPKZKJV-UHFFFAOYSA-N 0.000 claims description 4
- HWHDICSIECHQEK-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NC(C)C(C=1C=CC(Cl)=CC=1)CC1=CC=C(Cl)C=C1 HWHDICSIECHQEK-UHFFFAOYSA-N 0.000 claims description 4
- WLYDIBXQQLMVHF-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-(4-chlorophenyl)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)CC1=CC=C(Cl)C=C1 WLYDIBXQQLMVHF-UHFFFAOYSA-N 0.000 claims description 4
- NWAPTSXXXCBPQI-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-(4-chlorophenyl)propanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)CCC1=CC=C(Cl)C=C1 NWAPTSXXXCBPQI-UHFFFAOYSA-N 0.000 claims description 4
- KPVGMFKOLDHYTL-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-(4-hydroxyphenyl)propanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)CCC1=CC=C(O)C=C1 KPVGMFKOLDHYTL-UHFFFAOYSA-N 0.000 claims description 4
- QDTQEQZWVJSPDY-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-(cyclopropylamino)-2,2-dimethylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)CNC1CC1 QDTQEQZWVJSPDY-UHFFFAOYSA-N 0.000 claims description 4
- BLTBZYJBBWVNJN-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-(diethylamino)-2,2-dimethylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(C)NC(=O)C(C)(C)CN(CC)CC)CC1=CC=C(Cl)C=C1 BLTBZYJBBWVNJN-UHFFFAOYSA-N 0.000 claims description 4
- INBOFNXTRBVQDI-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-(tert-butylamino)-2,2-dimethylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(NC(=O)C(C)(C)CNC(C)(C)C)C)CC1=CC=C(Cl)C=C1 INBOFNXTRBVQDI-UHFFFAOYSA-N 0.000 claims description 4
- CPPHDOYAJCPJCP-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-hydroxy-2,2-dimethylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(NC(=O)C(C)(C)CO)C)CC1=CC=C(Cl)C=C1 CPPHDOYAJCPJCP-UHFFFAOYSA-N 0.000 claims description 4
- LSNQPHQDMXLLGX-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-3-methylbutanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(C)NC(=O)CC(C)C)CC1=CC=C(Cl)C=C1 LSNQPHQDMXLLGX-UHFFFAOYSA-N 0.000 claims description 4
- UYXFATAEHKKSFD-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-4-sulfamoylbutanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(NC(=O)CCCS(N)(=O)=O)C)CC1=CC=C(Cl)C=C1 UYXFATAEHKKSFD-UHFFFAOYSA-N 0.000 claims description 4
- SMNOBFCRTJPWHU-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-9-oxo-9-phenylnonanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)CCCCCCCC(=O)C1=CC=CC=C1 SMNOBFCRTJPWHU-UHFFFAOYSA-N 0.000 claims description 4
- IJAJZRDOTRFLRK-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]hexanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(C)NC(=O)CCCCC)CC1=CC=C(Cl)C=C1 IJAJZRDOTRFLRK-UHFFFAOYSA-N 0.000 claims description 4
- ZRUXJEYNUBXCLM-UHFFFAOYSA-N n-[3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-yl]-2-(5-chloropyridin-2-yl)oxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(Br)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=N1 ZRUXJEYNUBXCLM-UHFFFAOYSA-N 0.000 claims description 4
- DWILULKKFZECEP-UHFFFAOYSA-N n-[3-(3-bromophenyl)-4-(5-chloropyridin-2-yl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=NC=1CC(C=1C=C(Br)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 DWILULKKFZECEP-UHFFFAOYSA-N 0.000 claims description 4
- BEFFUUFCKQVYGN-UHFFFAOYSA-N n-[3-(3-chlorophenyl)-4-(4-chlorophenyl)butan-2-yl]-2-(5-chloropyridin-2-yl)oxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(Cl)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=N1 BEFFUUFCKQVYGN-UHFFFAOYSA-N 0.000 claims description 4
- MIFTZCBFKDWAGH-UHFFFAOYSA-N n-[3-(3-chlorophenyl)-4-(4-chlorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(Cl)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 MIFTZCBFKDWAGH-UHFFFAOYSA-N 0.000 claims description 4
- XKRNJPBSBDVDNO-UHFFFAOYSA-N n-[3-(3-cyanophenyl)octan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=CC(C#N)=CC=1C(CCCCC)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 XKRNJPBSBDVDNO-UHFFFAOYSA-N 0.000 claims description 4
- QJFWGLZMBHYIJM-UHFFFAOYSA-N n-[3-(4-chlorophenyl)-4-(2,4-dichlorophenyl)butan-2-yl]-2,2-dimethylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(NC(=O)C(C)(C)C)C)CC1=CC=C(Cl)C=C1Cl QJFWGLZMBHYIJM-UHFFFAOYSA-N 0.000 claims description 4
- RUWOPJYQDBIUML-UHFFFAOYSA-N n-[3-(5-chloropyridin-3-yl)-5-methylhexan-2-yl]-2-methyl-2-[3-(trifluoromethyl)pyridin-4-yl]oxypropanamide Chemical compound C=1N=CC(Cl)=CC=1C(CC(C)C)C(C)NC(=O)C(C)(C)OC1=CC=NC=C1C(F)(F)F RUWOPJYQDBIUML-UHFFFAOYSA-N 0.000 claims description 4
- ZDCFNYJKARMUMR-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(2,3-dihydroindol-1-yl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(N1C2=CC=CC=C2CC1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 ZDCFNYJKARMUMR-UHFFFAOYSA-N 0.000 claims description 4
- WBHFLFVOGSGSMM-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-(5-chloropyridin-2-yl)oxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=N1 WBHFLFVOGSGSMM-UHFFFAOYSA-N 0.000 claims description 4
- KTUBSUKLHVCCFM-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-methyl-2-[4-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=CC=N1 KTUBSUKLHVCCFM-UHFFFAOYSA-N 0.000 claims description 4
- KBJGVKJDEPJKSH-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 KBJGVKJDEPJKSH-UHFFFAOYSA-N 0.000 claims description 4
- RBXIDQGLNBXDOD-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-fluorophenyl)butan-2-yl]-2-methyl-2-[6-(trifluoromethyl)pyrimidin-4-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=NC=N1 RBXIDQGLNBXDOD-UHFFFAOYSA-N 0.000 claims description 4
- ABWAPQAPTFRUHD-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-pyridin-3-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CN=C1 ABWAPQAPTFRUHD-UHFFFAOYSA-N 0.000 claims description 4
- QPIALRVEBMCYCR-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-pyridin-2-ylbutan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1N=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QPIALRVEBMCYCR-UHFFFAOYSA-N 0.000 claims description 4
- SNFANYWKPTUQBC-UHFFFAOYSA-N n-[4-(5-chloropyridin-2-yl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=NC=1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 SNFANYWKPTUQBC-UHFFFAOYSA-N 0.000 claims description 4
- BBWVLURTUBPRIY-UHFFFAOYSA-N n-[4-(5-chloropyridin-2-yl)-3-phenylbutan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=NC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 BBWVLURTUBPRIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- QHCDMPFGZJPFKF-UHFFFAOYSA-N tert-butyl 4-[3-[3,4-bis(4-chlorophenyl)butan-2-ylamino]-3-oxopropyl]piperidine-1-carboxylate Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)CCC1CCN(C(=O)OC(C)(C)C)CC1 QHCDMPFGZJPFKF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- NWXPFHLRADFKRL-UHFFFAOYSA-N 2-(4-chlorophenoxy)-2-methylpropanamide Chemical compound NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 NWXPFHLRADFKRL-UHFFFAOYSA-N 0.000 claims description 3
- XUKJYGUVVIRPQH-UHFFFAOYSA-N 3,4-bis(4-chlorophenyl)butan-2-yl-(4-chlorophenyl)carbamic acid Chemical compound C=1C=C(Cl)C=CC=1N(C(O)=O)C(C)C(C=1C=CC(Cl)=CC=1)CC1=CC=C(Cl)C=C1 XUKJYGUVVIRPQH-UHFFFAOYSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 208000010235 Food Addiction Diseases 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 206010029333 Neurosis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 206010027175 memory impairment Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- PLEUHZRPGYJODB-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2,2-dimethylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C(NC(=O)C(C)(C)C)C)CC1=CC=C(Cl)C=C1 PLEUHZRPGYJODB-UHFFFAOYSA-N 0.000 claims description 3
- VAUDFGWHDRDSNB-UHFFFAOYSA-N n-[3-(5-chloropyridin-3-yl)-4-cyclobutylbutan-2-yl]-2-methyl-2-[3-(trifluoromethyl)pyridin-4-yl]oxypropanamide Chemical compound C1CCC1CC(C=1C=C(Cl)C=NC=1)C(C)NC(=O)C(C)(C)OC1=CC=NC=C1C(F)(F)F VAUDFGWHDRDSNB-UHFFFAOYSA-N 0.000 claims description 3
- 208000015238 neurotic disease Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 201000009032 substance abuse Diseases 0.000 claims description 3
- 231100000736 substance abuse Toxicity 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- ZOAXVBNCBQSPSY-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[3-(4-methoxyphenyl)-4-phenylbutan-2-yl]-2-methylpropanamide Chemical compound C1=CC(OC)=CC=C1C(C(C)NC(=O)C(C)(C)OC=1C=CC(Cl)=CC=1)CC1=CC=CC=C1 ZOAXVBNCBQSPSY-UHFFFAOYSA-N 0.000 claims description 2
- IKYKULSSMUZFBR-UHFFFAOYSA-N 2-methyl-n-[4-(4-methylphenyl)-3-phenylbutan-2-yl]-2-[4-(trifluoromethyl)phenoxy]propanamide Chemical compound C=1C=C(C)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=C1 IKYKULSSMUZFBR-UHFFFAOYSA-N 0.000 claims description 2
- BOZLAQWSKVCYCR-UHFFFAOYSA-N 2-methyl-n-[4-(4-methylphenyl)-3-phenylbutan-2-yl]-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(C)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 BOZLAQWSKVCYCR-UHFFFAOYSA-N 0.000 claims description 2
- OBBRHPQQCQTFBR-UHFFFAOYSA-N 3-chloro-5-[3-cyclobutyl-5-methyl-2-[4-[(2-methylpropan-2-yl)oxy]-6-(trifluoromethyl)-2H-pyridin-1-yl]hexan-2-yl]pyridine Chemical compound ClC=1C=C(C=NC=1)C(C)(C(CC(C)C)C1CCC1)N1CC=C(C=C1C(F)(F)F)OC(C)(C)C OBBRHPQQCQTFBR-UHFFFAOYSA-N 0.000 claims description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 claims description 2
- JIDXQZSUZOLFGJ-UHFFFAOYSA-N C(#N)C=1C=C(C=CC1)C(C(C)N1C(C=CC(=C1)C(F)(F)F)OC(C)(C)C)CC1CC1 Chemical compound C(#N)C=1C=C(C=CC1)C(C(C)N1C(C=CC(=C1)C(F)(F)F)OC(C)(C)C)CC1CC1 JIDXQZSUZOLFGJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- XCJLXFIGEMUOEE-UHFFFAOYSA-N acetamide;2,2,2-trifluoroacetic acid Chemical compound CC(N)=O.OC(=O)C(F)(F)F XCJLXFIGEMUOEE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 125000005002 aryl methyl group Chemical group 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- FQIODXHOJGYKFQ-UQBPGWFLSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3-cyanophenoxy)-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=CC(C#N)=C1 FQIODXHOJGYKFQ-UQBPGWFLSA-N 0.000 claims description 2
- BABVSXSJKSMMIB-UQBPGWFLSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(4-cyanophenoxy)-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=C(C#N)C=C1 BABVSXSJKSMMIB-UQBPGWFLSA-N 0.000 claims description 2
- UKXNFPASSFBHCD-HRAATJIYSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(5-chloropyrimidin-2-yl)oxy-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=NC=C(Cl)C=N1 UKXNFPASSFBHCD-HRAATJIYSA-N 0.000 claims description 2
- UXETXWSTRLOALZ-LAUBAEHRSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(6-chloropyridin-2-yl)oxy-2-methylpropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=CC(Cl)=N1 UXETXWSTRLOALZ-LAUBAEHRSA-N 0.000 claims description 2
- SMSGGGCPQLNXLR-MHECFPHRSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-[3-(trifluoromethyl)phenoxy]propanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=CC(C(F)(F)F)=C1 SMSGGGCPQLNXLR-MHECFPHRSA-N 0.000 claims description 2
- PVAFUYMWCZKQQA-HTAPYJJXSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-[4-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC(C(F)(F)F)=CC=N1 PVAFUYMWCZKQQA-HTAPYJJXSA-N 0.000 claims description 2
- NCDOGSPNODKFLN-FSWLIYMRSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-[[4-(trifluoromethyl)-1h-pyrimidin-4-yl]oxy]propanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1(C(F)(F)F)NC=NC=C1 NCDOGSPNODKFLN-FSWLIYMRSA-N 0.000 claims description 2
- HKUZZUBEPCDJLL-LAUBAEHRSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-pyrimidin-2-yloxypropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=NC=CC=N1 HKUZZUBEPCDJLL-LAUBAEHRSA-N 0.000 claims description 2
- OBCRERXZFHEQTJ-LAUBAEHRSA-N n-[(2s,3s)-4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-pyrimidin-4-yloxypropanamide Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=NC=N1 OBCRERXZFHEQTJ-LAUBAEHRSA-N 0.000 claims description 2
- BBWVLURTUBPRIY-HRAATJIYSA-N n-[(2s,3s)-4-(5-chloropyridin-2-yl)-3-phenylbutan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound N([C@@H](C)[C@@H](CC=1N=CC(Cl)=CC=1)C=1C=CC=CC=1)C(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 BBWVLURTUBPRIY-HRAATJIYSA-N 0.000 claims description 2
- XIIPLSUMBSMIOB-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2,2-dimethyl-3-piperidin-1-ylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC(Cl)=CC=1)C(C)NC(=O)C(C)(C)CN1CCCCC1 XIIPLSUMBSMIOB-UHFFFAOYSA-N 0.000 claims description 2
- UXNQJOQWFSGQTE-UHFFFAOYSA-N n-[3,4-bis(4-chlorophenyl)butan-2-yl]-2-hydroxy-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1C(O)C(=O)NC(C)C(C=1C=CC(Cl)=CC=1)CC1=CC=C(Cl)C=C1 UXNQJOQWFSGQTE-UHFFFAOYSA-N 0.000 claims description 2
- CGFSSXPXGHGJTC-UHFFFAOYSA-N n-[3-(2,3-dihydroindol-1-yl)-5-methylhexan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C1CC2=CC=CC=C2N1C(CC(C)C)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 CGFSSXPXGHGJTC-UHFFFAOYSA-N 0.000 claims description 2
- DWXAUAPUGGYTCP-UHFFFAOYSA-N n-[3-(3,4-dihydro-2h-quinolin-1-yl)-5-methylhexan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C1CCC2=CC=CC=C2N1C(CC(C)C)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 DWXAUAPUGGYTCP-UHFFFAOYSA-N 0.000 claims description 2
- XWVWAKXDOLPLPY-UHFFFAOYSA-N n-[3-(3-bromo-5-fluorophenyl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(Br)C=C(F)C=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 XWVWAKXDOLPLPY-UHFFFAOYSA-N 0.000 claims description 2
- SIHVMKYMBONCDC-UHFFFAOYSA-N n-[3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(Br)C=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 SIHVMKYMBONCDC-UHFFFAOYSA-N 0.000 claims description 2
- FHTSYUMUXSPHCL-UHFFFAOYSA-N n-[3-(3-cyano-5-fluorophenyl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(C=C(F)C=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 FHTSYUMUXSPHCL-UHFFFAOYSA-N 0.000 claims description 2
- RHSTXGRTLBPJKE-UHFFFAOYSA-N n-[3-(3-cyano-5-fluorophenyl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[6-(trifluoromethyl)pyrimidin-4-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(C=C(F)C=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=NC=N1 RHSTXGRTLBPJKE-UHFFFAOYSA-N 0.000 claims description 2
- MYPSHCMDAIBJQV-UHFFFAOYSA-N n-[3-(5-bromopyridin-3-yl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(Br)C=NC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 MYPSHCMDAIBJQV-UHFFFAOYSA-N 0.000 claims description 2
- WGNOHZPDEGYFGI-UHFFFAOYSA-N n-[3-(5-chloropyridin-3-yl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[3-(trifluoromethyl)pyridin-4-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(Cl)C=NC=1)C(C)NC(=O)C(C)(C)OC1=CC=NC=C1C(F)(F)F WGNOHZPDEGYFGI-UHFFFAOYSA-N 0.000 claims description 2
- PTUFXXBWTQSCEY-UHFFFAOYSA-N n-[3-(5-chloropyridin-3-yl)-4-cyclobutylbutan-2-yl]-2-methyl-2-[2-(trifluoromethyl)pyridin-4-yl]oxypropanamide Chemical compound C1CCC1CC(C=1C=C(Cl)C=NC=1)C(C)NC(=O)C(C)(C)OC1=CC=NC(C(F)(F)F)=C1 PTUFXXBWTQSCEY-UHFFFAOYSA-N 0.000 claims description 2
- BZFQYCQQXPCQBK-UHFFFAOYSA-N n-[3-(5-cyanopyridin-3-yl)-4-(3,4-difluorophenyl)butan-2-yl]-2-methyl-2-[6-(trifluoromethyl)pyrimidin-4-yl]oxypropanamide Chemical compound C=1C=C(F)C(F)=CC=1CC(C=1C=C(C=NC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=NC=N1 BZFQYCQQXPCQBK-UHFFFAOYSA-N 0.000 claims description 2
- JGRJQZODIUEJTA-UHFFFAOYSA-N n-[3-(5-cyanopyridin-3-yl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(C=NC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 JGRJQZODIUEJTA-UHFFFAOYSA-N 0.000 claims description 2
- JRHYTWDHEAJCIE-UHFFFAOYSA-N n-[4-(4-chloro-3-iodophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C(I)=CC=1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 JRHYTWDHEAJCIE-UHFFFAOYSA-N 0.000 claims description 2
- KTKLSBXRQVNEOR-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3,5-difluorophenyl)butan-2-yl]-2-methyl-2-pyridin-2-yloxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(F)C=C(F)C=1)C(C)NC(=O)C(C)(C)OC1=CC=CC=N1 KTKLSBXRQVNEOR-UHFFFAOYSA-N 0.000 claims description 2
- XJYUQAOTWWKWBJ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-cyano-5-fluorophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(C=C(F)C=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 XJYUQAOTWWKWBJ-UHFFFAOYSA-N 0.000 claims description 2
- IJFIWFQLUGPOIX-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[6-(trifluoromethyl)pyrimidin-4-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=C(C=CC=1)C#N)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=NC=N1 IJFIWFQLUGPOIX-UHFFFAOYSA-N 0.000 claims description 2
- XLZDVTNCFPUPNX-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(3,5-dichlorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(Cl)=CC(Cl)=C1 XLZDVTNCFPUPNX-UHFFFAOYSA-N 0.000 claims description 2
- VQOOAQMFUGGWKX-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-(5-chloropyridin-2-yl)oxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=N1 VQOOAQMFUGGWKX-UHFFFAOYSA-N 0.000 claims description 2
- UAFYQYJLBSEILF-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-(6-methylpyridin-2-yl)oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=CC(C)=N1 UAFYQYJLBSEILF-UHFFFAOYSA-N 0.000 claims description 2
- PVAFUYMWCZKQQA-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-[4-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=CC=N1 PVAFUYMWCZKQQA-UHFFFAOYSA-N 0.000 claims description 2
- VGXVGVLUSMHCIK-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-phenylbutan-2-yl]-2-methyl-2-[4-(trifluoromethyl)pyrimidin-2-yl]oxypropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1C=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=NC=CC(C(F)(F)F)=N1 VGXVGVLUSMHCIK-UHFFFAOYSA-N 0.000 claims description 2
- CHADKEHEAMHCGN-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-pyridin-2-ylbutan-2-yl]-2-(4-fluorophenoxy)-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C=1N=CC=CC=1)C(C)NC(=O)C(C)(C)OC1=CC=C(F)C=C1 CHADKEHEAMHCGN-UHFFFAOYSA-N 0.000 claims description 2
- RCVDIOBRLUTXHY-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-3-thiophen-3-ylbutan-2-yl]-2-(5-chloropyridin-2-yl)oxy-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1CC(C1=CSC=C1)C(C)NC(=O)C(C)(C)OC1=CC=C(Cl)C=N1 RCVDIOBRLUTXHY-UHFFFAOYSA-N 0.000 claims description 2
- UHMBSWRODDABEI-UHFFFAOYSA-N n-[4-cyclobutyl-3-(3,4-dihydro-2h-quinolin-1-yl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C1CCC1CC(N1C2=CC=CC=C2CCC1)C(C)NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 UHMBSWRODDABEI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
- ODPYMMDRXGGQGN-UHFFFAOYSA-N n-(2-butyloctyl)-2,2-dimethylpropanamide Chemical compound CCCCCCC(CCCC)CNC(=O)C(C)(C)C ODPYMMDRXGGQGN-UHFFFAOYSA-N 0.000 claims 6
- CBYJHXUBAJWNFG-UHFFFAOYSA-N 2,2-dimethyl-n-(2-octyldodecyl)propanamide Chemical compound CCCCCCCCCCC(CNC(=O)C(C)(C)C)CCCCCCCC CBYJHXUBAJWNFG-UHFFFAOYSA-N 0.000 claims 5
- ZUVFGQCLZCVEDM-UHFFFAOYSA-N 3,5,5-trimethyl-n-(2-octyldodecyl)hexanamide Chemical compound CCCCCCCCCCC(CCCCCCCC)CNC(=O)CC(C)CC(C)(C)C ZUVFGQCLZCVEDM-UHFFFAOYSA-N 0.000 claims 5
- MOUIKDILUGJZLJ-UHFFFAOYSA-N n-(2-butyloctyl)-3,5,5-trimethylhexanamide Chemical compound CCCCCCC(CCCC)CNC(=O)CC(C)CC(C)(C)C MOUIKDILUGJZLJ-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- GLBNTBLOLXXOFK-UHFFFAOYSA-N 2-(4-chlorophenoxy)propanamide Chemical compound NC(=O)C(C)OC1=CC=C(Cl)C=C1 GLBNTBLOLXXOFK-UHFFFAOYSA-N 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- NQRFFSGZONUPJS-UHFFFAOYSA-N n-[3-(3-bromo-5-fluorophenyl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[6-(trifluoromethyl)pyrimidin-4-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(Br)C=C(F)C=1)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=NC=N1 NQRFFSGZONUPJS-UHFFFAOYSA-N 0.000 claims 1
- RSVJZZNSSZLFRJ-UHFFFAOYSA-N n-[3-(5-bromopyridin-3-yl)-4-(4-fluorophenyl)butan-2-yl]-2-methyl-2-[4-(trifluoromethyl)pyridin-2-yl]oxypropanamide Chemical compound C=1C=C(F)C=CC=1CC(C=1C=C(Br)C=NC=1)C(C)NC(=O)C(C)(C)OC1=CC(C(F)(F)F)=CC=N1 RSVJZZNSSZLFRJ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 3
- 0 *C(*)C(*)N(*)C(*)=O Chemical compound *C(*)C(*)N(*)C(*)=O 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- DGGJYEPLMGDNKR-UHFFFAOYSA-N C=1C=CC=NC=1C(C(C)N(C(O)=O)C(C)(C)C)CC1=CC=C(Cl)C=C1 Chemical compound C=1C=CC=NC=1C(C(C)N(C(O)=O)C(C)(C)C)CC1=CC=C(Cl)C=C1 DGGJYEPLMGDNKR-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N CN(C)c1ccccc1 Chemical compound CN(C)c1ccccc1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36359702P | 2002-03-12 | 2002-03-12 | |
| US42835102P | 2002-11-22 | 2002-11-22 | |
| PCT/US2003/007320 WO2003077847A2 (en) | 2002-03-12 | 2003-03-07 | Substituted amides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006105912A Division JP5025980B2 (ja) | 2002-03-12 | 2006-04-07 | 置換アミド類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005519958A JP2005519958A (ja) | 2005-07-07 |
| JP2005519958A5 true JP2005519958A5 (https=) | 2006-01-19 |
| JP3813152B2 JP3813152B2 (ja) | 2006-08-23 |
Family
ID=28045319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003575901A Expired - Fee Related JP3813152B2 (ja) | 2002-03-12 | 2003-03-07 | 置換アミド類 |
| JP2006105912A Expired - Fee Related JP5025980B2 (ja) | 2002-03-12 | 2006-04-07 | 置換アミド類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006105912A Expired - Fee Related JP5025980B2 (ja) | 2002-03-12 | 2006-04-07 | 置換アミド類 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US6972295B2 (https=) |
| EP (1) | EP1496838B1 (https=) |
| JP (2) | JP3813152B2 (https=) |
| AT (1) | ATE486842T1 (https=) |
| CA (1) | CA2478183C (https=) |
| DE (1) | DE60334787D1 (https=) |
| NZ (1) | NZ534757A (https=) |
| WO (1) | WO2003077847A2 (https=) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| EP1490043A4 (en) | 2002-03-26 | 2007-05-30 | Merck & Co Inc | SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS |
| US20050154202A1 (en) * | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| EP1499306A4 (en) | 2002-04-12 | 2007-03-28 | Merck & Co Inc | BICYCLIC AMIDE |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| HUE028976T2 (en) * | 2003-06-17 | 2017-02-28 | Arena Pharm Inc | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| EP1641493A4 (en) * | 2003-06-30 | 2007-10-31 | Merck & Co Inc | RADIOACTIVELY MARKED CANNABINOID-1 RECEPTOR MODULATORS |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| CA2538291A1 (en) * | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
| WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| WO2005042490A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| FR2861302A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861300B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861301B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| WO2005039579A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| WO2005044785A1 (en) * | 2003-10-30 | 2005-05-19 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
| RU2360909C2 (ru) | 2004-01-28 | 2009-07-10 | Ф.Хоффманн-Ля Рош Аг | Новые спиропентациклические соединения |
| WO2005080334A1 (ja) * | 2004-02-23 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 新規へテロ環化合物 |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7687665B2 (en) * | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
| US7629470B2 (en) | 2004-07-08 | 2009-12-08 | Merck & Co., Inc. | Formation of tetra-substituted enamides and stereoselective reduction thereof |
| WO2006035759A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
| WO2006035760A1 (ja) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 皮膚疾患治療剤 |
| WO2006043518A1 (ja) * | 2004-10-18 | 2006-04-27 | Santen Pharmaceutical Co., Ltd. | 神経疾患治療剤 |
| CA2579227A1 (en) * | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as cb1 antagonists |
| RU2391337C2 (ru) | 2004-11-09 | 2010-06-10 | Ф.Хоффманн-Ля Рош Аг | Производные дибензосуберона |
| CN101115726A (zh) | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| SI1838677T1 (sl) | 2004-12-21 | 2010-01-29 | Arena Pharm Inc | Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida |
| SG158168A1 (en) | 2004-12-23 | 2010-01-29 | Arena Pharm Inc | 5ht2c receptor modulator compositions and methods of use |
| EP1846364A1 (en) * | 2005-01-25 | 2007-10-24 | Universita' Degli Studi di Siena | New potent and selective ligands of cannabinoid receptors |
| CA2610354C (en) | 2005-05-31 | 2011-03-29 | Pfizer Inc. | Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| CA2613678A1 (en) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| WO2007064273A1 (en) * | 2005-11-29 | 2007-06-07 | Astrazeneca Ab | Phenyl urea derivatives |
| ATE442368T1 (de) * | 2005-11-30 | 2009-09-15 | Hoffmann La Roche | 3-amino-2-arylpropylazaindole und anwendungen davon |
| JP2009517430A (ja) * | 2005-11-30 | 2009-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | ３−アミノ−１−アリールプロピルインドール類及びアザ置換インドール類 |
| AR059021A1 (es) * | 2006-01-18 | 2008-03-05 | Schering Corp | Moduladores de receptores cannabinoides |
| CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| EP2471779A1 (en) | 2006-04-03 | 2012-07-04 | Arena Pharmaceuticals, Inc. | Process for the resolution of a mixture of (R)- and (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| JP2009537523A (ja) * | 2006-05-15 | 2009-10-29 | メルク エンド カムパニー インコーポレーテッド | 三級アルコールのプロドラッグ |
| CA2652259A1 (en) * | 2006-05-18 | 2007-11-29 | Merck & Co., Inc. | Substituted esters as cannabinoid-1 receptor modulators |
| GB0611154D0 (en) * | 2006-06-06 | 2006-07-19 | Glaxo Group Ltd | Novel receptor antagonists and their methods of use |
| US20070287734A1 (en) * | 2006-06-09 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity |
| WO2007146890A2 (en) * | 2006-06-09 | 2007-12-21 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity |
| WO2008019351A2 (en) * | 2006-08-04 | 2008-02-14 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to diacylglycerol acyltransferase 1 |
| WO2008035023A1 (en) * | 2006-09-19 | 2008-03-27 | Cipla Limited | Polymorphs of rimonabant |
| JP5489333B2 (ja) | 2006-09-22 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 脂肪酸合成阻害剤を用いた治療の方法 |
| US8299241B2 (en) * | 2006-12-05 | 2012-10-30 | Arena Pharmaceuticals, Inc. | Processes for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| US20100048632A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine GPCR Agonists |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| US8088926B2 (en) * | 2007-05-18 | 2012-01-03 | Jenrin Discovery, Inc. | Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| WO2008142134A1 (en) * | 2007-05-24 | 2008-11-27 | Neurosearch A/S | Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions |
| EP2546232A1 (en) | 2007-06-20 | 2013-01-16 | Merck Sharp & Dohme Corp. | Diphenyl Substituted Alkanes |
| US8623873B2 (en) * | 2007-06-28 | 2014-01-07 | Intervet Inc. | Substituted piperazines as CB1 antagonists |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| WO2009048544A1 (en) * | 2007-10-10 | 2009-04-16 | Merck & Co., Inc. | Liquid pharmaceutical compositions for parenteral administration of a substituted amide |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| WO2009054929A1 (en) * | 2007-10-23 | 2009-04-30 | Merck & Co., Inc. | Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease |
| CN102015591B (zh) * | 2008-03-04 | 2014-01-29 | 艾尼纳制药公司 | 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法 |
| US8003672B2 (en) | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| JP5539322B2 (ja) * | 2008-04-22 | 2014-07-02 | イーライ リリー アンド カンパニー | Ｃｂ−１リガンドとしての１，５−ジフェニル−ピロリジン−２−オン化合物 |
| DK2280961T3 (da) * | 2008-04-22 | 2012-08-27 | Lilly Co Eli | 1,5-diphenyl-pyrrolidin-2-on-forbindelser som cb-1-ligander |
| AU2009256390A1 (en) * | 2008-06-03 | 2009-12-10 | Siga Technologies, Inc. | Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| EP2350020B1 (en) | 2008-10-03 | 2014-08-13 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
| WO2010144664A1 (en) | 2009-06-12 | 2010-12-16 | Schering Corporation | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
| US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011075688A1 (en) * | 2009-12-18 | 2011-06-23 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US20130101590A1 (en) | 2010-04-09 | 2013-04-25 | Heather A. Arnett | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| KR20130112848A (ko) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법 |
| US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| KR20140091458A (ko) | 2010-09-01 | 2014-07-21 | 아레나 파마슈티칼스, 인크. | 신장 손상을 갖는 개체에 대한 로카세린의 투여 |
| JP2013536859A (ja) | 2010-09-01 | 2013-09-26 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃアゴニストの非吸湿性塩 |
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| US20150166630A1 (en) | 2012-07-19 | 2015-06-18 | Amgen Inc. | Btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014058441A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| AR095883A1 (es) | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| KR102245345B1 (ko) | 2014-09-29 | 2021-04-28 | 조게닉스 인터내셔널 리미티드 | 의약품 배포 제어를 위한 제어 시스템 |
| EP3226972A4 (en) | 2014-12-01 | 2018-08-08 | Achelios Therapeutics, Inc. | Methods and compositions for treating migraine and conditions associated with pain |
| AR105025A1 (es) | 2015-06-19 | 2017-08-30 | Astellas Pharma Inc | Compuesto de imidazodiazepina |
| CA2991894A1 (en) | 2015-07-10 | 2017-01-19 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| PT4293009T (pt) | 2015-12-22 | 2025-09-08 | Zogenix International Ltd | Composições de fenfluramina e métodos de preparação das mesmas |
| CN116217731B (zh) | 2016-04-22 | 2025-12-30 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
| AU2017315273B2 (en) | 2016-08-24 | 2021-04-29 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| IL284752B2 (en) | 2019-01-15 | 2025-05-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Peripheral CB1 receptor inhibitors |
| EP4010316A1 (en) * | 2019-08-08 | 2022-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Novel peripheral cannabinoid-1 receptor antagonists |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2024196697A2 (en) * | 2023-03-17 | 2024-09-26 | Curadh Mtr | Compounds and constructs useful for targeting fibroblast activation protein |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US114495A (en) * | 1871-05-02 | Improvement in the carre ice-machine | ||
| US248956A (en) * | 1881-11-01 | Self-measuring oil-can | ||
| US58820A (en) * | 1866-10-16 | hazaed | ||
| US3277165A (en) * | 1962-02-08 | 1966-10-04 | Merck & Co Inc | Fumaramic acid derivatives |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| ZA821577B (en) * | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
| DE3574132D1 (en) * | 1984-05-28 | 1989-12-14 | Ciba Geigy Ag | Means for the protection of culture plants against the phytotoxic action of chloracetanilide herbicides |
| GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| EP0268190B1 (en) * | 1986-11-20 | 1993-06-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
| IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| US5278316A (en) * | 1989-06-29 | 1994-01-11 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives |
| FR2654725B1 (fr) * | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH03220168A (ja) * | 1990-01-22 | 1991-09-27 | Mitsubishi Kasei Corp | １―フェニルアルキル―３―フェニル尿素誘導体 |
| US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US20020006963A1 (en) | 1992-06-23 | 2002-01-17 | Young James W. | Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| CA2115183A1 (en) * | 1993-02-12 | 1994-08-13 | Takashi Nomoto | Substituted amic acid derivatives |
| US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
| JP3176469B2 (ja) | 1993-03-04 | 2001-06-18 | 株式会社クボタ | 精米設備の糠処理装置 |
| DE4332738A1 (de) * | 1993-09-25 | 1995-03-30 | Basf Ag | Racematspaltung primärer und sekundärer Amine durch Enzym-katalysierte Acylierung |
| AU7947594A (en) * | 1993-10-27 | 1995-05-22 | Merck Sharp & Dohme Limited | Substituted amides as tachykinin antagonists |
| CA2176140A1 (en) | 1993-11-24 | 1995-06-01 | Meng Hsin Chen | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| AU680736B2 (en) * | 1994-02-25 | 1997-08-07 | Banyu Pharmaceutical Co., Ltd. | Carbapenem derivative |
| JPH08165276A (ja) * | 1994-12-14 | 1996-06-25 | Dainippon Pharmaceut Co Ltd | ２−アルキルアミノ−１−フェニルエタノール誘導体 |
| IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
| US20020006964A1 (en) * | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| AU6688896A (en) | 1995-08-17 | 1997-03-12 | Amgen, Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| WO1997016189A1 (en) | 1995-11-01 | 1997-05-09 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| AU7505196A (en) | 1995-11-07 | 1997-05-29 | Banyu Pharmaceutical Co., Ltd. | Cyclic amic acid derivatives |
| WO1997018833A1 (en) | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| EP0887340A4 (en) | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| AU1619197A (en) * | 1996-02-07 | 1997-08-28 | Banyu Pharmaceutical Co., Ltd. | Cyclic amic acid derivatives |
| WO1997046250A1 (en) | 1996-06-04 | 1997-12-11 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) |
| US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| CA2269660A1 (en) | 1996-10-31 | 1998-05-07 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| WO1998028427A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| DE69822449T2 (de) | 1997-01-21 | 2005-01-27 | Smithkline Beecham Corp. | Neue cannabinoidrezeptor-modulatoren |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| US6011048A (en) | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
| CN1246845A (zh) | 1997-02-04 | 2000-03-08 | 纳幕尔杜邦公司 | 杀菌的羧酰胺 |
| TR199902012T2 (xx) | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
| EP0979228A4 (en) | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| EP0992239B1 (en) * | 1997-04-23 | 2003-03-12 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide y receptor antagonist |
| FR2764602B1 (fr) * | 1997-06-11 | 1999-07-30 | Oreal | Composition cosmetique comprenant un amide et nouveaux amides |
| US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
| EP0920864A1 (en) | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US6043385A (en) | 1997-12-16 | 2000-03-28 | Hoffman-La Roche Inc. | Vitamin D derivatives |
| AU2337599A (en) * | 1998-01-23 | 1999-08-09 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| EP1140914A1 (en) * | 1998-12-18 | 2001-10-10 | Warner-Lambert Company | Non-peptide nk1 receptors antagonists |
| US6344481B1 (en) * | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
| AU2935200A (en) | 1999-04-30 | 2000-11-17 | Pfizer Products Inc. | Compounds for the treatment of obesity |
| ES2542868T3 (es) | 1999-06-14 | 2015-08-12 | Vivus, Inc. | Terapia de combinación para el tratamiento de diabetes asociada con la obesidad |
| TR200502284T2 (tr) | 1999-07-06 | 2005-08-22 | Endorecherche, Inc. | Kilo alımını tedavi ve/veya önleme metotları |
| US6380224B1 (en) | 1999-07-28 | 2002-04-30 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| PT1741446E (pt) | 2000-01-21 | 2008-05-09 | Novartis Pharma Ag | Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| AU2873401A (en) | 2000-02-11 | 2001-08-20 | Karl Frederik Venter | A training device |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| UA74367C2 (uk) | 2000-03-23 | 2005-12-15 | Сольве Фармас'Ютікалз Б.В. | ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ) |
| CN100494182C (zh) * | 2000-05-12 | 2009-06-03 | 基酶有限公司 | 肿瘤坏死α因子信号的调节因子 |
| FR2809621B1 (fr) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
| ATE481385T1 (de) * | 2000-05-31 | 2010-10-15 | Santen Pharmaceutical Co Ltd | (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren |
| US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| GB0019008D0 (en) * | 2000-08-04 | 2000-09-27 | Astrazeneca Ab | Therapeutic compounds |
| US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| WO2002019998A2 (en) | 2000-09-08 | 2002-03-14 | Eli Lilly And Company | A method of treating weight gain associated with atypical antipsychotic use |
| EP1322628A2 (en) | 2000-09-14 | 2003-07-02 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| CZ20031012A3 (en) | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| US6784172B2 (en) * | 2000-11-03 | 2004-08-31 | Wyeth | Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| CN1473156A (zh) | 2000-11-10 | 2004-02-04 | - | 嘧啶衍生物及其作为神经肽y受体配体的用途 |
| NZ526174A (en) | 2000-12-21 | 2004-12-24 | Schering Corp | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
| IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| SK287592B6 (sk) | 2001-03-22 | 2011-03-04 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazolové deriváty, ktoré majú CB1-antagonistickú účinnosť, spôsob ich prípravy a použitie |
| ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| EP1421077A4 (en) | 2001-08-31 | 2004-11-17 | Univ Connecticut | NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| HUP0401567A3 (en) | 2001-09-21 | 2005-06-28 | Solvay Pharm Bv | Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them |
| HRP20030913A2 (en) | 2001-09-21 | 2004-06-30 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| JP2005532982A (ja) | 2001-09-24 | 2005-11-04 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満の処置のためのピロール誘導体の製造及び使用 |
| EP1430032A2 (en) | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Substituted amides for the treatment of neurological disorders |
| GT200200188A (es) | 2001-09-24 | 2003-06-25 | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad | |
| JP2005504100A (ja) | 2001-09-24 | 2005-02-10 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満の治療のための１，５，６，７−テトラヒドロピロロ［３，２−ｃ］ピリジン誘導体の製造法および使用 |
| CA2463441A1 (en) | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| AU2003209388A1 (en) * | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| EP1490043A4 (en) | 2002-03-26 | 2007-05-30 | Merck & Co Inc | SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| US20050154202A1 (en) | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
| EP1499306A4 (en) | 2002-04-12 | 2007-03-28 | Merck & Co Inc | BICYCLIC AMIDE |
| WO2004009015A2 (en) | 2002-07-18 | 2004-01-29 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
| MY134457A (en) | 2002-11-22 | 2007-12-31 | Merck & Co Inc | Substituted amides |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| FR2849032B1 (fr) | 2002-12-23 | 2006-04-28 | Sanofi Synthelabo | Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique |
| CN100395234C (zh) | 2003-01-02 | 2008-06-18 | 霍夫曼-拉罗奇有限公司 | 新cb1受体反激动剂 |
| WO2004110368A2 (en) * | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of hypertension |
| EP1635832A2 (en) * | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| WO2005000217A2 (en) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
| AU2004252109B2 (en) | 2003-06-11 | 2010-04-08 | Merck Sharp & Dohme Corp. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| EP1641493A4 (en) | 2003-06-30 | 2007-10-31 | Merck & Co Inc | RADIOACTIVELY MARKED CANNABINOID-1 RECEPTOR MODULATORS |
| CA2538291A1 (en) | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
| CN101027075A (zh) | 2004-09-24 | 2007-08-29 | 默克公司 | 用于治疗肥胖的组合疗法 |
| US20080200376A1 (en) | 2004-10-29 | 2008-08-21 | Maccoss Malcolm | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction |
| US20060270650A1 (en) * | 2005-05-26 | 2006-11-30 | Macneil Tanya | Combination therapy for the treatment of obesity |
-
2003
- 2003-03-07 NZ NZ534757A patent/NZ534757A/en unknown
- 2003-03-07 AT AT03714051T patent/ATE486842T1/de not_active IP Right Cessation
- 2003-03-07 WO PCT/US2003/007320 patent/WO2003077847A2/en not_active Ceased
- 2003-03-07 EP EP03714051A patent/EP1496838B1/en not_active Expired - Lifetime
- 2003-03-07 JP JP2003575901A patent/JP3813152B2/ja not_active Expired - Fee Related
- 2003-03-07 DE DE60334787T patent/DE60334787D1/de not_active Expired - Lifetime
- 2003-03-07 CA CA2478183A patent/CA2478183C/en not_active Expired - Fee Related
- 2003-03-12 US US10/387,265 patent/US6972295B2/en not_active Expired - Lifetime
-
2005
- 2005-04-19 US US11/109,076 patent/US20050234061A1/en not_active Abandoned
-
2006
- 2006-04-07 JP JP2006105912A patent/JP5025980B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-01 US US12/012,463 patent/US7550489B2/en not_active Expired - Fee Related
-
2009
- 2009-04-16 US US12/386,336 patent/US7816534B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519958A5 (https=) | ||
| CA2478183A1 (en) | Substituted amides | |
| JP2021520340A5 (https=) | ||
| EP0567982B1 (en) | Azole compounds, their production and use | |
| KR20050083563A (ko) | 카나비노이드-1 수용체에서 활성인 치환된 아미드 | |
| US20040087798A1 (en) | Novel amide compounds | |
| EP1028111A1 (en) | Amide derivatives or salts thereof | |
| CN87102873A (zh) | 苯基哌嗪抗心律不齐剂及其制备方法 | |
| EA012206B1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
| US7915424B2 (en) | Pyridyl derivatives and their use as mGlu5 antagonists | |
| CN1246847A (zh) | 作为Xa因子抑制剂的含氮杂芳族化合物 | |
| CZ2003468A3 (cs) | Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy | |
| EP1575901A2 (en) | Substituted amides | |
| CN102686572A (zh) | 用于治疗cns病的噁唑啉衍生物 | |
| TW200526641A (en) | Amidopyrazole derivatives | |
| AU2003297562A1 (en) | COMPOUNDS WITH MIXED PDE-INHIBITORY AND Beta-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | |
| US20070117978A1 (en) | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | |
| CN105916850A (zh) | 作为激酶抑制剂的取代的二烷基(氧撑)-λ4-硫烷亚基烟酰胺衍生物 | |
| JP4559690B2 (ja) | ピラゾール誘導体とその製造中間体及びそれらの製造方法、並びにそれらを有効成分とする除草剤 | |
| CA2462390A1 (en) | Anthranilic acid amides and pharmaceutical use thereof | |
| JPWO2019193342A5 (https=) | ||
| CN1115204A (zh) | 植物病害控制剂 | |
| ZA200406647B (en) | Substituted amides | |
| JPH101474A (ja) | 治療に有用なキノキサリン誘導体 | |
| AU2007201276B2 (en) | Substituted amides |